{"Clinical Trial ID": "NCT00432172", "Intervention": ["INTERVENTION 1:", "Standard (basic) treatment of Group 2", "Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles followed by docetaxel (D) 100 mg/m2 iv every 21 days for 4 cycles.", "INTERVENTION 2:", "Group 2 (basic) Selective treatment", "Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles followed by docetaxel (D) 100 mg/m2 iv and carboplatin (Cb) (zone under curve = 6 mg/mL) iv every 21 days for 4 cycles."], "Eligibility": ["Incorporation criteria:", "\"Knowledgeful written consent.", "- Breast cancer with histological diagnosis.", "- Negative human epidermal growth factor receptor 2 (HER2) tumours defined as immunohistochemistry (IHQ) 0.1+.", "There is no sign of suspicion of metastatic disease.", "Age >= 18 years.", "State of performance (Karnofsky index) >= 80 (ECOG 0.1).", "Adequate cardiac function by ECG in the previous 12 weeks.", "Hematology: neutrophils >= 1.5 x10^9/l; platelets >= 100 x10^9/l; hemoglobin >= 10 g/dl.", "Adequate hepatic function: total bilirubin <= 1x Upper normal limit (LUN); Aspartate aminotransferase (AST) (SGOT) and Alanine aminotransferase (ALT) (SGPT) <= 2.5 x LUN; alkaline phosphatase <= 2.5 x LUN.", "Adequate renal function: creatinine <= 1 x UNL; creatinine clearance >= 60 ml/min.", "* Patients able to comply with treatment and study follow-up.", "Negative pregnancy test in the previous 14 days.", "- Exclusion criteria:", "- HER2 positive tumours (defined as IHQ 3+ or positive fluorescence hybridization in situ [FISH]).", "Prior systemic treatment of breast cancer (immunotherapy, hormone therapy, chemotherapy).", "Previous treatment with anthracyclines or taxanes (pallitaxel, docetaxel) for any previous malignancy.", "- Prior radiation therapy for breast cancer.", "Invasive bilateral breast cancer.", "Pregnant or lactating women.", "Previous category >= 2 motor or sensory neurotoxicity (National Cancer Institute Common Criteria for Toxicity [NICTC].", "Other serious comorbidities: congestive heart failure or unstable angina; history of myocardial infarction in the previous year; uncontrolled hypertension (HT); high-risk arrhythmias; history of significant neurological or psychiatric disorders; uncontrolled active infection; active peptic ulcer; unstable diabetes mellitus; resting dyspnea; or chronic oxygen treatment.", "Previous or present history of different neoplasms of breast cancer, except skin carcinoma, cervical carcinoma in situ or any other tumour treated curatively and without recurrence in the last 10 years; canalal carcinoma in situ in the same breast; lobular carcinoma in situ.", "Chronic treatment with corticosteroids.", "Contraindications for the administration of corticosteroids.", "- Concomitant treatment with another cancer treatment.", "Men."], "Results": ["Performance measures:", "Pathological response for basal group 2", "The pathological response in luminal group 1 was not pre-determined even as a secondary outcome. The pathological response was evaluated after surgery, using Miller & Payne's criteria, which stratifies responses based on the proportion of remaining tumour and post-chemotherapy changes, separately evaluating the response in the breast and axil. Grades 1 to 4 are classified as a partial pathological response (PRp) and Grade 5 as a complete pathological response (PRc).", "Time limit: up to 24 weeks", "Results 1:", "\u2022 Arm/group title: Group 2 standard standard treatment", "Description of the arm/group: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles followed by docetaxel (D) 100 mg/m2 iv every 21 days for 4 cycles.", "Total number of participants analysed: 46", "Type of measure: Number of participants", "Unit of measure: Participants Grade 5 16 34.8%", "Grade 4: 5 10.9%", "Grade 3: 11 23.9%", "Grade 2: 8 17.4%", "Year 1 : 5 10.9%", "Not available: 1 2.2%", "Results 2:", "Title of arm/group: Group 2 Basic Selective Treatment", "Description of the arm/group: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D) 100 mg/m2 iv and carboplatin (Cb) (zone below curve = 6 mg/mL) iv every 21 days for 4 cycles.", "Total number of participants analysed: 47", "Type of measure: Number of participants", "Unit of measure: Participants Grade 5, Grade 14, 29.8%", "Grade 4: 11 23.4%", "Grade 3: 8 17.0%", "Grade 2: 9 19.1%", "Level 1: 4 8.5%", "Not available: 1 2.1%"], "Adverse Events": ["Undesirable Events 1:", "Total: 5/45 (11.11 per cent)", "- Neutrophils/granulocytes (ANC/AGC) * [1]0.45 (0.00 %)", "- Neutrophils/granulocytes (ANC/AGC) * [2]0.45 (0.00 %)", "Decompensation for diabetes * 0/45 (0.00 %)", "Diarrhoea * [2]0.45 (0.00 %)", "- Mucositis/stomatitis and vomiting * [3]0.45 (0.00 %)", "Pancreatitis * [4]1/45 (2.22%)", "Febrile neutropenia * [2]3/45 (6.67 %)", "Adverse Events 2:", "Total: 0/46 (0.00 per cent)", "- Neutrophils/granulocytes (ANC/AGC) * [1]0/46 (0.00 %)", "- Neutrophils/granulocytes (ANC/AGC) * [2]0/46 (0.00 %)", "Decompensation for diabetes * 0/46 (0.00 %)", "Diarrhoea * [2]0/46 (0.00 %)", "- Mucositis/stomatitis and vomiting * [3]0/46 (0.00 %)", "Pancreatitis * [4]0/46 (0.00 %)", "Febrile neutropenia * [2]0/46 (0.00 %)", "\u2022 Pulmonary/ upper respiratory tract infection NOS * [5]0/46 (0.00 %)"]}